Supplementary Documents [IFRS]

Financial results for the first six months of the fiscal year 2026 (FY2026)

Astellas Pharma Inc.

- Q2 YTD/FY2026 Financial Results
  - Six months ended September 30, 2026
  - Three months ended September 30, 2026
- Pipeline list

Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[Six months ended September 30, 2026]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY25 APR. - SEP.	FY26 APR. - SEP.	Change	Change (%)	FY25 Full Year	Initial Forecasts FY26 Full Year	Revised Forecasts FY26 Full Year	Change from FY25 (%)
Revenue	1,030.1	1,270.9	240.7	23.4%	2,139.2	2,220.0	2,330.0	8.9%
Cost of sales	200.4	247.9	47.5	23.7%	408.4	445.0	455.0	11.4%
Gross profit	829.8	1,023.0	193.2	23.3%	1,730.8	1,775.0	1,875.0	8.3%
SG&A expenses	403.8	430.4	26.5	6.6%	860.3	800.0	815.0	-5.3%
XTANDI co-promotion fee in the United States	127.2	131.8	4.7	3.7%	248.2	216.0	230.0	-7.3%
SG&A excl. the above	276.7	298.5	21.9	7.9%	612.1	584.0	585.0	-4.4%
Ratio to Revenue	26.9%	23.5%			28.6%	26.3%	25.1%	
R&D expenses	143.3	167.7	24.4	17.0%	314.8	355.0	360.0	14.3%
Ratio to Revenue	13.9%	13.2%			14.7%	16.0%	15.5%	
Amortisation of intangible assets	65.5	71.3	5.8	8.8%	136.0			
Gain on divestiture of intangible assets	4.0	-	-4.0	-	4.3			
Share of profit (loss) of investments accounted for using equity method	-1.6	-1.4	0.2	-	-1.8			
Other income	5.2	2.5	-2.7	-52.7%	32.8			
Net foreign exchange gains	0.5	0.5	0.0	6.4%	4.9			
Fair value remeasurements on contingent consideration	4.1	-	-4.1	-	16.9			
Other expenses	25.4	38.2	12.8	50.3%	72.4			
Impairment losses for intangible assets	16.4	29.8	13.4	81.8%	52.8			
Restructuring costs	4.9	4.4	-0.5	-10.8%	9.9			
Operating profit	199.4	316.6	117.2	58.8%	382.6	395.0	460.0	20.2%
Ratio to Revenue	19.4%	24.9%			17.9%	17.8%	19.7%	
Finance income	3.8	7.9	4.0	105.7%	8.0			
Finance expenses	8.6	7.0	-1.6	-19.0%	14.1			
Profit before tax	194.6	317.5	122.8	63.1%	376.6	385.0	450.0	19.5%
Income tax expense	47.0	75.9	28.9	61.6%	85.0			
Profit	147.6	241.5	93.9	63.6%	291.6	300.0	350.0	20.0%
Comprehensive income	164.6	221.9	57.3	34.8%	449.5			

2. Consolidated Results (Core Basis)

Unit: B¥

	FY25 APR. - SEP.	FY26 APR. - SEP.	Change	Change (%)	FY25 Full Year	Initial Forecasts FY26 Full Year	Revised Forecasts FY26 Full Year	Change from FY25 Change (%)
Revenue	1,030.1	1,270.9	240.7	23.4%	2,139.2	2,220.0	2,330.0	8.9%
Cost of sales	200.4	247.9	47.5	23.7%	408.4	445.0	455.0	11.4%
Gross profit	829.8	1,023.0	193.2	23.3%	1,730.8	1,775.0	1,875.0	8.3%
SG&A expenses	403.8	430.4	26.5	6.6%	860.3	800.0	815.0	-5.3%
XTANDI co-promotion fee in the United States	127.2	131.8	4.7	3.7%	248.2	216.0	230.0	-7.3%
SG&A excl. the above	276.7	298.5	21.9	7.9%	612.1	584.0	585.0	-4.4%
Ratio to Revenue	26.9%	23.5%			28.6%	26.3%	25.1%	
R&D expenses	143.3	167.7	24.4	17.0%	314.8	355.0	360.0	14.3%
Ratio to Revenue	13.9%	13.2%			14.7%	16.0%	15.5%	
Operating profit	282.6	424.9	142.3	50.3%	555.7	620.0	700.0	26.0%
Ratio to Revenue	27.4%	33.4%			26.0%	27.9%	30.0%	
Finance income	3.8	7.9	4.0	105.7%	8.0			
Finance expenses	8.6	7.0	-1.6	-19.0%	14.1			
Profit before tax	277.9	425.8	148.0	53.3%	549.6			
Income tax expense	66.4	94.3	27.9	42.1%	125.2			
Profit	211.5	331.5	120.0	56.8%	424.4	460.0	520.0	22.5%

3. Exchange Rate

Unit: ¥

	FY25 APR. - SEP.Ave.	FY26 APR. - SEP.Ave.	FY25 End	FY26 Q2 End	FY25 Full Year	Initial Forecasts FY26 Full Year	Revised Forecasts FY26 Full Year
USD/Yen	146	159	159	157	151	150	158
EUR/Yen	168	184	183	178	175	180	181

* Fx impacts: Revenue +99.3 billion yen and Core operating profit +41.2 billion yen

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY25 APR. - SEP.			FY26 APR. - SEP.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	**1,030.1**	**-**	**1,030.1**	**1,270.9**	**-**	**1,270.9**
Cost of sales	200.4	-	200.4	247.9	-	247.9
Gross profit	**829.8**	**-**	**829.8**	**1,023.0**	**-**	**1,023.0**
SG&A expenses	403.8	-	403.8	430.4	-	430.4
R&D expenses	143.3	-	143.3	167.7	-	167.7
Amortisation of intangible assets *	65.5	-65.5	-	71.3	-71.3	-
Gain on divestiture of intangible assets *	4.0	-4.0	-	-	-	-
Share of profit (loss) of investments accounted for using equity method *	-1.6	1.6	-	-1.4	1.4	-
Other income *	5.2	-5.2	-	2.5	-2.5	-
Other expenses *	25.4	-25.4	-	38.2	-38.2	-
Operating profit	**199.4**	**83.3**	**282.6**	**316.6**	**108.4**	**424.9**
Finance income	3.8	-	3.8	7.9	-	7.9
Finance expenses	8.6	-	8.6	7.0	-	7.0
Profit before tax	**194.6**	**83.3**	**277.9**	**317.5**	**108.4**	**425.8**
Income tax expense	47.0	19.4	66.4	75.9	18.4	94.3
Profit	**147.6**	**63.8**	**211.5**	**241.5**	**90.0**	**331.5**

* "Amortisation of intangible assets", "Gain on divestiture of intangible assets", "Share of profit (loss) of investments accounted for using equity method", "Other income" and "Other expenses" are excluded from Core basis results.
"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

5. Revenue by Region

Unit: B¥

		FY25 APR. - SEP.	FY26 APR. - SEP.	Change	Change (%)	FY25 Full Year	Initial Forecasts FY26 Full Year	Revised Forecasts FY26 Full Year	Change from FY25 FY26 Change (%)
Revenue		1,030.1	1,270.9	240.7	23.4%	2,139.2	2,220.0	2,330.0	8.9%
	United States	457.1	576.8	119.7	26.2%	940.2			
	Ratio to Revenue	44.4%	45.4%			44.0%			
	Japan	142.9	160.8	17.9	12.5%	289.0			
	Ratio to Revenue	13.9%	12.7%			13.5%			
	Established Markets	264.9	304.0	39.1	14.8%	563.6			
	Ratio to Revenue	25.7%	23.9%			26.3%			
	China	49.7	68.9	19.2	38.5%	101.5			
	Ratio to Revenue	4.8%	5.4%			4.7%			
	International Markets	111.5	154.2	42.6	38.2%	230.7			
	Ratio to Revenue	10.8%	12.1%			10.8%			

- Established Markets: Europe, Canada, etc.
- China: China, Hong Kong
- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

6. Per Share Information

	FY25 APR. - SEP.	FY26 APR. - SEP.	FY25 Full Year	Initial Forecasts FY26 Full Year	Revised Forecasts FY26 Full Year
The number of shares issued (thousand)	1,809,663	1,809,663	1,809,663		
Treasury Shares (thousand)	18,447	16,540	18,170		
The number of shares issued after deducting Treasury Shares (thousand)	1,791,215	1,793,122	1,791,492		
Earnings per share (yen)	82.44	134.83	162.77	167.46	195.22
Earnings per share (yen) core basis	118.08	185.02	237.01	256.77	290.04
Dividend per share (yen)	39	40	78	80	80

- The numbers of shares stated in the business report are presented by disregarding any number of shares less than the specified units.

7. Investment in Property, Plant and Equipment
Depreciation/Amortisation

Unit: B¥

	FY25 APR. - SEP.	FY26 APR. - SEP.	Change	Change (%)	FY25 Full Year	Initial Forecasts FY26 Full Year	Revised Forecasts FY26 Full Year	Change from FY25 FY26 Change (%)
Investment in Property, Plant and Equipment	16.9	22.7	5.7	33.7%	49.3	55.0	55.0	11.5%
Depreciation (PP&E)	21.8	22.3	0.5	2.3%	43.6	45.0	45.0	3.1%
Amortisation of Intangible Assets (incl. software, etc.)	73.3	77.0	3.7	5.1%	151.0	155.0	155.0	2.7%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

8. Sales of major brands

1) Global

Unit: B¥

		FY25 APR. - SEP.	FY26 APR. - SEP.	Change	Change (%)	FY25 Full Year	Initial Forecasts FY26 Full Year	Revised Forecasts FY26 Full Year	Change from FY25 Change (%)
Strategic Brands Total		220.5	333.9	113.4	51.4%	480.3	610.0	680.0	41.6%
PADCEV		102.5	158.3	55.9	54.5%	221.2			
	United States	60.4	93.2	32.9	54.5%	129.2			
	Japan	10.1	9.9	-0.2	-2.1%	20.3			
	Established Markets	20.1	37.6	17.5	87.1%	52.2			
	China	7.2	9.6	2.4	33.2%	9.8			
	International Markets	4.6	7.9	3.3	71.2%	9.6			
IZERVAY		34.1	56.2	22.0	64.5%	77.6			
	United States	34.1	55.8	21.6	63.4%	77.5			
	Japan	-	0.3	0.3	-	0.1			
VYLOY		26.6	45.9	19.3	72.7%	63.1			
	United States	12.2	20.6	8.4	68.9%	29.9			
	Japan	6.4	7.2	0.8	11.9%	13.7			
	Established Markets	4.3	7.1	2.7	63.6%	11.3			
	China	3.2	9.3	6.1	190.8%	6.7			
	International Markets	0.5	1.8	1.3	287.5%	1.5			
VEOZAH		22.9	30.7	7.7	33.8%	46.6			
	United States	20.4	25.4	4.9	24.1%	40.6			
	Established Markets	2.1	3.9	1.9	89.7%	4.8			
	International Markets	0.4	1.3	0.9	238.6%	1.1			
XOSPATA		34.4	42.9	8.4	24.5%	71.8			
	United States	15.3	18.2	2.9	18.8%	32.0			
	Japan	2.5	2.9	0.3	13.1%	5.0			
	Established Markets	11.4	13.1	1.6	14.4%	23.0			
	China	2.0	3.2	1.2	63.0%	4.6			
	International Markets	3.2	5.6	2.3	72.2%	7.2			
XTANDI		477.0	533.7	56.7	11.9%	960.8	910.0	930.0	-3.2%
	United States	247.8	261.2	13.4	5.4%	483.7			
	Japan	32.1	37.3	5.2	16.1%	64.8			
	Established Markets	141.3	152.4	11.2	7.9%	291.0			
	China	10.7	14.1	3.4	31.3%	24.7			
	International Markets	45.0	68.6	23.6	52.4%	96.5			
BETANIS/MYRBETRIQ/BETMIGA		86.5	119.5	33.0	38.1%	189.7	180.0	210.0	10.7%
	United States	30.8	59.3	28.5	92.7%	72.3			
	Japan	11.1	11.0	-0.2	-1.7%	22.3			
	Established Markets	34.2	35.7	1.5	4.5%	73.3			
	China	0.5	0.6	0.1	20.9%	0.9			
	International Markets	9.9	12.9	3.0	30.5%	20.9			
PROGRAF		103.2	114.3	11.1	10.8%	207.7			

- Established Markets: Europe, Canada, etc.
- China: China, Hong Kong
- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.
- PADCEV (United States): Co-promotion revenue from Pfizer
- VEOZAH: Approved as “VEOZA” in ex-US

2) Revenue by Region

(1) United States

Unit: M$

		FY25 APR. - SEP.	FY26 APR. - SEP.	Change	Change (%)	FY25 Full Year
Revenue		3,131	3,621	490	15.7%	6,236
	PADCEV	413	585	172	41.6%	857
	IZERVAY	234	350	116	49.7%	514
	VYLOY	84	129	46	54.8%	198
	VEOZAH	140	159	19	13.8%	269
	XOSPATA	105	114	9	8.9%	212
	XTANDI	1,697	1,640	-58	-3.4%	3,209
	MYRBETRIQ	211	372	162	76.6%	480
	CRESEMBA	172	224	51	29.8%	362

(2) Japan

Unit: B¥

		FY25 APR. - SEP.	FY26 APR. - SEP.	Change	Change (%)	FY25 Full Year
Revenue		142.9	160.8	17.9	12.5%	289.0
	PADCEV	10.1	9.9	-0.2	-2.1%	20.3
	IZERVAY	-	0.3	0.3	-	0.1
	VYLOY	6.4	7.2	0.8	11.9%	13.7
	XOSPATA	2.5	2.9	0.3	13.1%	5.0
	XTANDI	32.1	37.3	5.2	16.1%	64.8
	BETANIS	11.1	11.0	-0.2	-1.7%	22.3
	EVENITY	34.3	46.5	12.2	35.6%	74.2

(3) Established Markets

Unit: M€

		FY25 APR. - SEP.	FY26 APR. - SEP.	Change	Change (%)	FY25 Full Year
Revenue		1,575	1,650	74	4.7%	3,224
	PADCEV	120	204	85	70.8%	299
	VYLOY	26	38	13	49.3%	64
	VEOZA	12	21	9	73.1%	27
	XOSPATA	68	71	3	4.4%	132
	XTANDI	840	827	-13	-1.5%	1,665
	BETMIGA	203	194	-9	-4.7%	419

- Established Markets: Europe, Canada, etc.

(4) China

Unit: B¥

	FY25 APR. - SEP.	FY26 APR. - SEP.	Change	Change (%)	FY25 Full Year
Revenue	49.7	68.9	19.2	38.5%	101.5
PADCEV	7.2	9.6	2.4	33.2%	9.8
VYLOY	3.2	9.3	6.1	190.8%	6.7
XOSPATA	2.0	3.2	1.2	63.0%	4.6
XTANDI	10.7	14.1	3.4	31.3%	24.7
BETMIGA	0.5	0.6	0.1	20.9%	0.9

- China: China, Hong Kong

(5) International Markets

Unit: B¥

	FY25 APR. - SEP.	FY26 APR. - SEP.	Change	Change (%)	FY25 Full Year
Revenue	111.5	154.2	42.6	38.2%	230.7
PADCEV	4.6	7.9	3.3	71.2%	9.6
VYLOY	0.5	1.8	1.3	287.5%	1.5
VEOZA	0.4	1.3	0.9	238.6%	1.1
XOSPATA	3.2	5.6	2.3	72.2%	7.2
XTANDI	45.0	68.6	23.6	52.4%	96.5
BETMIGA	9.9	12.9	3.0	30.5%	20.9

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

9. Consolidated statements of financial position

Unit: B¥

	FY25 End	FY26 Q2 End	Change
Assets	**3,567.0**	**3,527.8**	**-39.3**
Non-current assets	**2,145.1**	**2,083.4**	**-61.7**
Property, plant and equipment	358.4	358.2	-0.2
Goodwill	441.2	438.0	-3.2
Intangible assets	996.9	934.2	-62.8
Investments accounted for using equity method	20.3	19.4	-0.9
Deferred tax assets	146.6	137.8	-8.8
Other financial assets	138.3	146.5	8.2
Other non-current assets	43.4	49.3	5.9
Current assets	**1,421.9**	**1,444.4**	**22.5**
Inventories	331.0	324.0	-7.0
Trade and other receivables	746.8	813.5	66.7
Income tax receivable	15.0	12.3	-2.6
Other financial assets	9.6	11.7	2.1
Other current assets	38.0	44.7	6.7
Cash and cash equivalents	281.6	238.2	-43.4

Unit: B¥

	FY25 End	FY26 Q2 End	Change
Equity and Liabilities	**3,567.0**	**3,527.8**	**-39.3**
Equity	**1,830.9**	**1,983.4**	**152.5**
Equity attributable to owners of the parent	**1,829.0**	**1,981.7**	**152.7**
Share capital	103.0	103.0	-
Capital surplus	185.2	182.1	-3.1
Treasury shares	-34.9	-31.4	3.6
Retained earnings	902.8	1,082.1	179.3
Other components of equity	673.0	645.9	-27.1
Non-controlling interest	**1.8**	**1.7**	**-0.1**
Liabilities	**1,736.2**	**1,544.4**	**-191.8**
Non-current liabilities	**517.8**	**444.6**	**-73.2**
Bonds and borrowings	320.0	270.0	-50.0
Income tax payable	6.7	4.3	-2.4
Deferred tax liabilities	1.3	4.2	3.0
Retirement benefit liabilities	21.5	21.6	0.1
Provisions	8.2	4.9	-3.3
Other financial liabilities	89.1	84.5	-4.6
Other non-current liabilities	71.0	55.1	-15.9
Current liabilities	**1,218.4**	**1,099.8**	**-118.6**
Bonds and borrowings	246.0	154.9	-91.0
Trade and other payables	199.8	187.6	-12.2
Income tax payable	68.9	49.3	-19.7
Provisions	23.5	16.3	-7.2
Refund liabilities	422.6	461.4	38.8
Other financial liabilities	22.3	21.3	-1.0
Other current liabilities	235.3	209.0	-26.3

10. Employees

Number of employees

	FY25 Q2 End	FY26 Q2 End	FY25 Q4 End
Total	13,672	14,290	14,099

11. Shareholders

	FY25 Q2 End	FY26 Q2 End
Banks	35.2%	33.0%
Securities	7.1%	6.6%
Other companies	2.3%	2.2%
Foreign companies	38.9%	45.4%
Individuals and others	16.5%	12.8%
Treasury Stock*	0.0%	0.0%

* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust and ESOP (Employee Stock Ownership Plan) trust.

[Three months ended September 30, 2026]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY26			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue	640.9	26.7%	629.9	20.1%
Cost of sales	122.7	29.4%	125.2	18.6%
Gross profit	518.2	26.1%	504.8	20.5%
SG&A expenses	215.1	9.2%	215.3	4.1%
XTANDI co-promotion fee in the United States	67.5	7.2%	64.4	0.2%
SG&A excl. the above	147.6	10.1%	150.9	5.9%
Ratio to Revenue	23.0%		24.0%	
R&D expenses	81.7	14.0%	86.0	20.1%
Ratio to Revenue	12.8%		13.7%	
Amortisation of intangible assets	35.7	8.9%	35.6	8.8%
Share of profit (loss) of investments accounted for using equity method	-0.8	-	-0.5	-
Other income	3.9	-10.4%	-1.5	-
Net foreign exchange gains	3.2	-	-2.6	-
Other expenses	4.3	-79.8%	33.9	736.2%
Impairment losses for intangible assets	0.0	-99.6%	29.7	954.0%
Restructuring costs	1.9	-33.6%	2.5	19.0%
Operating profit	184.5	94.9%	132.1	26.1%
Ratio to Revenue	28.8%		21.0%	
Finance income	5.1	207.8%	2.7	26.7%
Finance expenses	3.1	-47.1%	3.8	42.4%
Profit before tax	186.5	106.3%	130.9	25.7%
Income tax expense	44.8	103.5%	31.2	24.7%
Profit	141.8	107.2%	99.8	26.0%
Comprehensive income	183.6	426.2%	38.3	-70.5%

2. Consolidated Results (Core Basis)

Unit: B¥

	FY26			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue	640.9	26.7%	629.9	20.1%
Cost of sales	122.7	29.4%	125.2	18.6%
Gross profit	518.2	26.1%	504.8	20.5%
SG&A expenses	215.1	9.2%	215.3	4.1%
XTANDI co-promotion fee in the United States	67.5	7.2%	64.4	0.2%
SG&A excl. the above	147.6	10.1%	150.9	5.9%
Ratio to Revenue	23.0%		24.0%	
R&D expenses	81.7	14.0%	86.0	20.1%
Ratio to Revenue	12.8%		13.7%	
Operating profit	221.4	55.6%	203.5	45.0%
Ratio to Revenue	34.5%		32.3%	
Finance income	5.1	207.8%	2.7	26.7%
Finance expenses	3.1	-47.1%	3.8	42.4%
Profit before tax	223.4	61.9%	202.4	44.8%
Income tax expense	53.0	58.9%	41.4	25.0%
Profit	170.5	62.8%	161.0	50.9%

3. Revenue by Region

Unit: B¥

		FY26			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		640.9	26.7%	629.9	20.1%
	United States	288.8	28.5%	288.0	23.9%
	Ratio to Revenue	45.1%		45.7%	
	Japan	79.6	15.5%	81.2	9.7%
	Ratio to Revenue	12.4%		12.9%	
	Established Markets	152.2	18.2%	151.8	11.5%
	Ratio to Revenue	23.7%		24.1%	
	China	32.1	8.9%	36.8	81.4%
	Ratio to Revenue	5.0%		5.8%	
	International Markets	85.4	60.5%	68.7	17.9%
	Ratio to Revenue	13.3%		10.9%	

- Established Markets: Europe, Canada, etc.
- China: China, Hong Kong
- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

4. Investment in Property, Plant and Equipment
Depreciation/Amortisation

Unit: B¥

	FY26			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Investment in Property, Plant and Equipment	10.1	108.2%	12.6	4.0%
Depreciation (PP&E)	11.1	-0.5%	11.2	5.3%
Amortisation of Intangible Assets (incl. software, etc.)	38.8	5.8%	38.2	4.3%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

5. Sales of major brands

1) Global

Unit: B¥

		FY26			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Strategic Brands Total		160.3	43.2%	173.6	59.9%
PADCEV		75.5	36.0%	82.8	76.5%
	United States	45.4	43.2%	47.8	66.9%
	Japan	4.9	-4.1%	5.0	0.1%
	Established Markets	17.5	84.4%	20.1	89.5%
	China	4.1	-45.1%	5.6	-
	International Markets	3.6	100.6%	4.3	52.4%
IZERVAY		27.2	70.3%	29.0	59.4%
	United States	27.0	69.3%	28.8	58.1%
	Japan	0.1	-	0.2	-
VYLOY		21.1	50.7%	24.7	97.5%
	United States	9.9	68.5%	10.7	69.2%
	Japan	3.5	13.7%	3.6	10.2%
	Established Markets	3.4	104.0%	3.7	38.3%
	China	3.6	9.8%	5.7	-
	International Markets	0.8	502.0%	1.0	206.6%
VEOZAH		14.9	54.8%	15.7	18.6%
	United States	12.5	45.8%	12.8	8.4%
	Established Markets	1.9	107.2%	2.1	76.4%
	International Markets	0.5	254.1%	0.8	229.3%
XOSPATA		21.6	27.3%	21.3	21.7%
	United States	9.6	30.0%	8.6	8.5%
	Japan	1.5	11.5%	1.4	14.9%
	Established Markets	6.5	16.1%	6.6	12.7%
	China	1.5	49.3%	1.7	77.5%
	International Markets	2.6	51.3%	3.0	95.7%
XTANDI		276.6	18.7%	257.1	5.3%
	United States	131.7	7.4%	129.5	3.4%
	Japan	18.9	18.9%	18.4	13.3%
	Established Markets	76.4	10.1%	76.0	5.8%
	China	7.1	47.1%	7.1	18.6%
	International Markets	42.5	110.4%	26.1	5.2%
BETANIS/MYRBETRIQ/BETMIGA		63.4	47.5%	56.1	28.9%
	United States	32.0	107.8%	27.3	77.5%
	Japan	5.7	0.4%	5.3	-3.8%
	Established Markets	19.0	14.1%	16.8	-4.6%
	China	0.3	-0.4%	0.3	49.5%
	International Markets	6.4	28.6%	6.5	32.4%
PROGRAF		58.5	14.2%	55.9	7.4%

- Established Markets: Europe, Canada, etc.
- China: China, Hong Kong
- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.
- PADCEV (United States): Co-promotion revenue from Pfizer
- VEOZAH: Approved as “VEOZA” in ex-US

2）Revenue by Region

(1) United States

Unit: M$

		FY26			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		1,812	16.5%	1,809	14.8%
	PADCEV	285	29.9%	301	54.8%
	IZERVAY	169	53.5%	181	46.4%
	VYLOY	62	52.8%	67	56.7%
	VEOZAH	79	32.2%	81	0.1%
	XOSPATA	60	17.9%	54	0.5%
	XTANDI	826	-2.6%	814	-4.2%
	MYRBETRIQ	201	88.4%	171	64.5%
	CRESEMBA	108	34.5%	116	25.6%

(2) Japan

Unit: B¥

		FY26			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		79.6	15.5%	81.2	9.7%
	PADCEV	4.9	-4.1%	5.0	0.1%
	IZERVAY	0.1	-	0.2	-
	VYLOY	3.5	13.7%	3.6	10.2%
	XOSPATA	1.5	11.5%	1.4	14.9%
	XTANDI	18.9	18.9%	18.4	13.3%
	BETANIS	5.7	0.4%	5.3	-3.8%
	EVENITY	23.2	40.3%	23.3	31.2%

(3) Established Markets

Unit: M€

		FY26			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		821	4.5%	829	4.9%
	PADCEV	95	63.2%	110	77.9%
	VYLOY	18	80.5%	20	28.9%
	VEOZA	10	83.3%	11	65.0%
	XOSPATA	35	2.7%	36	6.0%
	XTANDI	413	-2.6%	415	-0.4%
	BETMIGA	102	0.9%	92	-10.2%

- Established Markets: Europe, Canada, etc.

(4) China

Unit: B¥

	FY26			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue	32.1	8.9%	36.8	81.4%
PADCEV	4.1	-45.1%	5.6	-
VYLOY	3.6	9.8%	5.7	-
XOSPATA	1.5	49.3%	1.7	77.5%
XTANDI	7.1	47.1%	7.1	18.6%
BETMIGA	0.3	-0.4%	0.3	49.5%

- China: China, Hong Kong

(5) International Markets

Unit: B¥

	FY26			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue	85.4	60.5%	68.7	17.9%
PADCEV	3.6	100.6%	4.3	52.4%
VYLOY	0.8	502.0%	1.0	206.6%
VEOZA	0.5	254.1%	0.8	229.3%
XOSPATA	2.6	51.3%	3.0	95.7%
XTANDI	42.5	110.4%	26.1	5.2%
BETMIGA	6.4	28.6%	6.5	32.4%

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China. As of Oct 2026

Underlined items indicate changes from the previous announcement in Aug 2026.

Strategic Brands (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
enfortumab vedotin **ASG-22ME** **(PADCEV)**	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Cisplatin-ineligible muscle-invasive bladder cancer (combo with pembrolizumab)	Japan Filed (Jan 2026) China Filed (Jul 2026) NCT03924895	In-house [Co-development with Pfizer]	
			Cisplatin-eligible muscle-invasive bladder cancer (combo with pembrolizumab)	Japan Filed (May 2026) China Filed (Jul 2026) Europe Approved (Oct 2026) NCT04700124		
			Bladder-sparing muscle-invasive bladder cancer (combo with pembrolizumab)	P-III NCT07566156		
gilteritinib **ASP2215** **(XOSPATA)**	Small molecule	FLT3 inhibitor	Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III NCT04027309	In-house	
			Post-chemotherapy maintenance acute myeloid leukemia	P-III		
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-II NCT05520567		
			Acute myeloid leukemia in pediatric patients	P-III NCT04293562		
			ALK-positive non-small cell lung cancer	P-I NCT07140016		
zolbetuximab **IMAB362** **(VYLOY)**	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma (combo with pembrolizumab and chemotherapy)	P-III NCT06901531	In-house (Ganymed)	

Strategic Brands (2/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
fezolinetant **ESN364** **(VEOZAH***)**	Small molecule	NK3 receptor antagonist	Vasomotor symptoms due to menopause	China Filed (Oct 2026) NCT06812754 Japan Filed (Aug 2026) NCT06206408 NCT06206421	In-house (Ogeda)	
			Vasomotor symptoms in breast cancer patients on adjuvant endocrine therapy	P-III NCT06440967		
avacincaptad pegol **(IZERVAY)**	Pegylated RNA aptamer	Complement C5 inhibitor	Geographic atrophy secondary to age-related macular degeneration	China Filed (May 2026)	In-house (Iveric Bio)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.
*** Approved as "VEOZA" in ex-US.

Updates from the previous announcement (Aug 2026):
enfortumab vedotin: Removed the description of approval in EU for cisplatin-ineligible muscle-invasive bladder cancer in Jun 2026. Removed the description of approval in US for cisplatin-eligible muscle-invasive bladder cancer in Jul 2026. Approved in Europe in Oct 2026 for cisplatin-eligible muscle-invasive bladder cancer.
fezolinetant: Filed in Japan in Aug 2026 and China in Oct 2026 for vasomotor symptoms due to menopause.

Programs with Focus Area approach (1/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
Immuno-oncology	**ASP2138**	T-cell engager	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma	P-III NCT07673887	Xencor [Discovered through collaborative research]	
				Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I NCT05365581 NCT07024615		
	ASP1002	T-cell engager	Anti-Claudin 4 and anti-CD137 bispecific antibody	Cancer	P-I NCT05719558	In-house	
	ASP6958/VIR-5500	T-cell engager	Anti-PSMA and anti-CD3 T-cell engager	Prostate cancer	P-I NCT05997615	Vir Biotechnology	
	ASP2998	Antibody-drug conjugate (ADC)	TROP2 targeted dual-payload iADC	Cancer	P-I NCT07287995	Sutro Biopharma [Discovered through collaborative research]	
	ASP388B	Antibody-drug conjugate (ADC)	B7-H3 targeted dual-payload iADC	Cancer	P-I NCT07730021	Sutro Biopharma [Discovered through collaborative research]	
Induced Proximity	**setidegrasib**	Small molecule	KRAS G12D degrader	Pancreatic ductal adenocarcinoma	P-III NCT07409272	In-house	
				Non-small cell lung cancer	P-III NCT07566052		
	ASP5834	Small molecule	Pan-KRAS degrader	Cancer	P-I NCT07094204	In-house	

Programs with Focus Area approach (2/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
Genetic regulation	**zocaglusagene nuzaparvovec AT845**	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-II NCT04174105	In-house (Audentes Therapeutics)	
	ASP2957	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-I NCT07052929	Kate Therapeutics/ Novartis	
Blindness and Regeneration	**ASP7317**	Cell therapy	Retinal pigment epithelial cells	Geographic atrophy secondary to age-related macular degeneration	P-I NCT03178149	In-house (Ocata Therapeutics)	
	ASP2020	Cell therapy	Retinal pigment epithelial cells (Universal Cell technology)	Stargardt-type macular dystrophies	P-I NCT07734064	In-house (Universal Cells)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Aug 2026):
ASP2138: Entered into Phase 3 for gastric and gastroesophageal junction adenocarcinoma.
ASP388B: Entered into Phase 1 for cancer.
setidegrasib: Entered into Phase 3 for non-small cell lung cancer.
ASP2020: Entered into Phase 1 for Stargardt-type macular dystrophies.

Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
mirabegron **YM178**	Small molecule	β_3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients (aged 6 months to less than 3 years)	Europe P-III NCT05621616	In-house	
roxadustat **ASP1517/FG-4592**	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease in pediatric patients	Europe P-III NCT05970172	Kyntra Bio	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.
ASP546C/XNW27011	Antibody-drug conjugate (ADC)	Claudin 18.2-targeted ADC	Cancer	P-I NCT07488676	Evopoint Biosciences	Astellas has worldwide rights excluding China's mainland, Hong Kong, Macau, and Taiwan.

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Aug 2026):
ASP5541: Discontinued Phase 2 program for prostate cancer.

Rx+ Program

As of Oct 2026

Category	Program	Concept	Status*	Partner	Remarks
Implantable medical device	**Akyva**	Implantable device for underactive bladder	Early feasibility study	(iota Biosciences)	

* The list shows the most advanced stage if the stages are different depending on the region.

Updates from the previous announcement (Aug 2026):
BlueStar: Discontinued the development in pivotal study (Japan).
pudexacianinium chloride: Discontinued the development in Phase 3.